| Sep 26 |
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
|
| Aug 26 |
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
|
| Aug 19 |
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
|
| Aug 2 |
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
|
| Aug 1 |
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
|
| Jul 31 |
NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy
|
| Jul 24 |
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
|
| Jul 11 |
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
|
| Jun 24 |
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
|
| Jun 20 |
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
